Prof Bill Dougall
Bill Dougall is currently Senior Principal Research Fellow in Immunology in Cancer and Infection at the QIMR Berghofer Medical Research Institute. Until recently, he was Scientific Director of Oncology Research at Amgen. He was part of the research group at Immunex that identified RANK and RANKL, and subsequently demonstrated the obligate role of RANK in osteoclastogenesis using genetic models. At Amgen, he was Global Research lead for denosumab in oncology and led a basic research effort as part of the preclinical and clinical development of RANKL antagonists. His research in this area helped to define the RANK–RANKL signalling pathway, and he led the preclinical development of denosumab in cancer. Additional research interests include osteotropism of breast and prostate cancer, development of the mammary gland and basic mechanisms of breast cancer. In oncology, he has experience at all stages of pre-clinical development and design of P1/P2 clinical trials as well as experience filing INDs and BLAs with U.S. FDA and EMA. He received his Ph.D. in biochemistry and molecular biology at the University of Florida, Gainesville, Florida, USA, and completed a postdoctoral fellowship at the Department of Pathology, Division of Immunology, University of Pennsylvania, Philadelphia, USA.